Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Quercetin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 10/20 | 1.00 |
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.97 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 4/20 | 0.97 |
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.97 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.97 |
| ▸ | THRB known ✓ | P10828 | 3/20 | 0.97 |
| ▸ | SYK known ✓ | P43405 | 3/20 | 0.97 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.97 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.97 |
| ▸ | GSK3A known ✓ | P49840 | 2/20 | 0.97 |
| ▸ | GSK3B known ✓ | P49841 | 2/20 | 0.97 |
| ▸ | PIK3CG known ✓ | P48736 | 2/20 | 0.97 |
| ▸ | MMP1 known ✓ | P03956 | 2/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.97 |
| ▸ | CXCR1 known ✓ | P25024 | 1/20 | 0.97 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL29695492 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29597013 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29738299 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL28067078 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL1658852 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29449339 | 0.99 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL118425 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29351036 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL19723 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL17629824 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055360-A | Quercetin-hexahydric alcohol eutectic and preparation method thereof | 量子生物桥私人有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12605334-B2 | Method of enhancing the efficacy and stability of ingredients in suspensions | Solésence, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260034171-A1 | Composition for Improving Cognitive Function | PERRY STEPHEN C (US) | 2026-02-05 | — | — | US | claimed |
| US-20260007711-A1 | NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEIN | PONO LIFESTYLE, LLC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4551043-A2 | ADDITIVE FOR FOOD, DRINK AND PHARMACEUTICAL PRODUCTS TO IMPROVE HEALTH AND WELL-BEING | RB2 Enterprises, Llc (US) | 2025-05-14 | — | — | EP | claimed |
| US-20250120913-A1 | STABLE QUERCETIN NANOSUSPENSIONS | SIRONA BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | claimed |
| US-12251426-B2 | Pharmacological compositions for the treatment and prevention of coronavirus disease | Jager, Rama D. (US) | 2025-03-18 | — | — | US | claimed |
| EP-4387642-B1 | HERBAL COMPOSITION FOR BREAST CANCER PREVENTION | MANN KEVEHAZI LAURA (GB) | 2025-02-19 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| US-20030105031-A1 | Methods for the treatment of skin disorders | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| US-6368617-B1 | Dietary supplement | RELIV' INTERNATIONAL, INC. | 2002-04-09 | — | — | US | claimed |
| US-6291533-B1 | Dietary supplements for each specific blood type | VITAMERICA, INC. | 2001-09-18 | — | — | US | claimed |
| WO-1999041984-A9 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | HUTCHINSON FRED CANCER RES (US) | 1999-11-04 | — | — | WO | claimed |
| US-5972999-A | MIXTURE OF A SUGAR, ANTIOXIDANT AND AMINO ACID | UNILEVER NV (NL) | 1999-10-26 | — | — | US | claimed |
| WO-1999041984-A1 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1999-08-26 | — | — | WO | claimed |
| US-5804168-A | PRIMARY ANTIOXIDANT, ANTIINFLAMMATORY AGENT, AND IMMUNITY-BOOSTING COMPONENT | UNILEVER NV (NL) | 1998-09-08 | — | — | US | claimed |
| US-5804594-A | APPLYING A COMPOSITION INCLUDING A SUGAR COMPOUND THAT IS CONVERTED TO A GLYCOSAMINOGLYCAN TO THICKEN SKIN, A PRIMARY ANTIOXIDANT TO INHIBIT FORMATION OF COLLAGENASE AND ELASTASE AND AT LEAST ONE AMINO ACID | UNILEVER NV (NL) | 1998-09-08 | — | — | US | claimed |
| EP-0667245-A1 | Recording sheets containing alcohols and saccharides | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034171-A1 | Composition for Improving Cognitive Function | PHOSPHO1, PSEN1, S100B | MEN1 3089/4885ACHE 32/4885HDAC6 2784/4885 |
| US-20030105031-A1 | Methods for the treatment of skin disorders | TYR, CUTA, NFATC1 | MEN1 4748/4885ACHE 918/4885HDAC6 2042/4885 |
| US-20260007711-A1 | NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEIN | VDR, RNMT, CD14 | MEN1 3796/4885ACHE 162/4885HDAC6 403/4885 |
| US-12605334-B2 | Method of enhancing the efficacy and stability of ingredients in suspensions | CUTA, ABCG2, CCNC | MEN1 2459/4885ACHE 3275/4885HDAC6 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.